No Data
Estimating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): The abemaciclib active pharmaceutical ingredient workshop and formulation workshop have been completed, and can be put into commercial production after approval.
On November 1, Changshan Pharmaceutical (300255.SZ) stated on the investor interaction platform that abenpeptide is currently in the evaluation stage of pharmaceutical regulatory authorities and has not yet obtained marketing approval. The company's abenpeptide active pharmaceutical ingredient workshop and formulation workshop have been completed, and can be put into commercial production after approval, with preparations for sales after approval already underway, including team building, marketing strategy, etc.
Changshan Pharmaceutical: Report for the third quarter of 2024
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): The net income in the first three quarters was 72.90 million yuan, a year-on-year increase of 101.88%.
On October 29th, Changshan Biochemical Pharmaceutical (300255.SZ) released the third quarter report for the third quarter of 2024, achieving revenue of 0.784 billion yuan, a 31.20% year-on-year decrease; net income attributable to shareholders of the listed company was 7.2901 million yuan, a 101.88% year-on-year increase; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -28.1493 million yuan; basic earnings per share was 0.01 yuan.
Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Shareholder Returns Have Been Incredible, Earning 349% in 5 Years
Changshan Biochemical Gets Approval From Niger for Thrombosis Drug
Investor Optimism Abounds Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) But Growth Is LackingNo Data
No Data
